Quarterly ResultMay 6, 2026, 07:03 AM
Immunocore Q1 Net Sales $106.7M, Net Income $13.0M; KIMMTRAK 5-yr OS
AI Summary
Immunocore reported strong first-quarter 2026 financial results, with KIMMTRAK net sales reaching $106.7 million, a 14% increase year-over-year. The company achieved a net income of $13.0 million, up from $5.0 million in Q1 2025. A significant highlight was the oral presentation at AACR, showing KIMMTRAK doubled the likelihood of being alive at five years for metastatic uveal melanoma patients. Immunocore also provided updates on its pipeline, including progress in trials for advanced cutaneous melanoma and autoimmune diseases, and maintained a strong cash position of $845 million.
Key Highlights
- KIMMTRAK Q1 2026 net sales: $106.7 million, up 14% year-over-year.
- Net income for Q1 2026: $13.0 million, compared to $5.0 million in Q1 2025.
- Diluted income per share for Q1 2026: $0.25, up from $0.10 in Q1 2025.
- Cash, cash equivalents, and marketable securities: $844.9 million as of March 31, 2026.
- KIMMTRAK 5-year overall survival rate: 16% vs 8% in control arm for mUM patients.
- R&D expenses for Q1 2026: $61.1 million, up from $56.5 million in Q1 2025.
- SG&A expenses for Q1 2026: $37.9 million, down from $40.2 million in Q1 2025.